Evidence map›Paper›PMID 41042905›Full record

ArticleJournal of viral hepatitis2025

Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties.

Christopher J Gonzalez, Clarence N Perez-Mejia, Noelia Hernandez, Shashi N Kapadia, Jeff Niederdeppe, Arpan Dharia, Zoi Papalamprakopoulou, Andrew H Talal, Audrey R Lloyd, Ricardo Franco and 2 more

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christopher J GonzalezDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0003-2916-4175
Clarence N Perez-MejiaDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Noelia HernandezDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Shashi N KapadiaDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0001-6363-2839
Jeff NiederdeppeCornell Jeb E. Brooks School of Public Policy and Department of Communication, Cornell University, Ithaca, New York, USA.ORCID https://orcid.org/0000-0001-7686-1526
Arpan DhariaDivision of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Zoi PapalamprakopoulouDivision of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Andrew H TalalDivision of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Audrey R LloydDepartment of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Ricardo FrancoDepartment of Medicine, Miller School of Medicine, Miami, Florida, USA.
Martin F ShapiroDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Elaine WethingtonDepartment of Psychology, College of Human Ecology, Cornell University, Ithaca, New York, USA.

Funding

CTSA K12 Program at the University of Alabama at BirminghamK12TR004769 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Renee A. Heffron, Lucio Miele · 2024 to 2026
$4.8M
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods StudyR01DK123205 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAPIRO, MARTIN F. · 2020 to 2024
$3.1M
Integrated Care for Hepatitis C: Current Uptake & Impact on Future TreatmentK01DA048172 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI KAPADIA, SHASHI · 2019 to 2023
$948k
Kaleida Health FoundationNCATS NIH HHS K12 TR004769NIDA NIH HHS K01 DA048172NIDA NIH HHS K01DA048172NIDDK NIH HHS R01 DK123205NIDDK NIH HHS R01DK123205Patient-Centered Outcomes Research Institute HIS-1507-31640
6 · The paper itself

Abstract

objectiveTo identify specialty-specific influences in administering HCV treatment among primary care, gastroenterology/hepatology, infectious diseases, and addiction specialties, and strategies to potentially eliminate HCV. STUDY SETTING AND

designQualitative study using remote interviews with healthcare providers in New York and Alabama who treated or screened patients for HCV, purposefully sampling for specialty, clinical setting, and HCV treatment experience. Data sources and Analytic Sample: Interviews occurred 9/2021-8/2022. Transcripts were analyzed using a hybrid inductive-deductive approach; a content analysis identified codes arising uniquely within specialties.

resultsThirty-six providers were interviewed: primary care (n = 9), addiction medicine (n = 12), infectious diseases (n = 9), and gastroenterology/hepatology (n = 6). Distinct challenges and facilitators emerged across specialties. Primary care and addiction providers similarly emphasized the convenience and usual practice of referring patients to specialists for HCV treatment, while infectious disease and gastroenterology noted challenges with patients not completing the referrals. Primary care providers expressed wanting training and peer support related to treatment provision. Addiction providers described structural barriers, such as lacking on-site phlebotomy services and patients' competing health concern prioritization, but highlighted strategies to improve treatment access, including trust-building. Infectious disease providers highlighted using patient navigators to overcome logistical barriers, while gastroenterologists emphasized collaborative relationships, particularly with addiction specialists. Specialty-specific opportunities emerged regarding training, collaboration, navigation, and infrastructure.

conclusionsEliminating HCV requires addressing specialty-specific concerns for providers managing HCV. Potential opportunities include dissemination of specialty-tailored training, facilitating interdisciplinary care and desired cross-specialty collaborations, and overcoming unique infrastructural needs. Future research should evaluate implementation strategies addressing these specialty-specific needs.

Indexed as

Disease EradicationHealth PersonnelHepatitis CAdultAlabamaFemaleHumansInterviews as TopicMaleMiddle AgedNew YorkPrimary Health CareQualitative ResearchReferral and Consultationbarriersfacilitatorshepatitis cprimary carespecialty

Identifiers

PMID41042905
PMCPMC12624374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.